How to Buy Orchard Therapeutics Stock
Orchard Therapeutics PLC
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States.
Orchard Therapeutics stock last closed at $5.17, up 3.92% from the previous day, and has increased 12.39% in one year. It has overperformed other stocks in the Biotechnology industry by 0.11 percentage points. Orchard Therapeutics stock is currently +43.57% from its 52-week low of $3.60, and -28.19% from its 52-week high of $7.20.
At the moment, there are 255.26M ORTX shares outstanding. The market cap of ORTX is $131.97M. In the past 24 hours, 21,013 ORTX shares were traded.
How to Buy Orchard Therapeutics Stock
Not sure how to invest in Orchard Therapeutics stock? Here's how.
- Figure out where to buy Orchard Therapeutics stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you figure out where to buy Orchard Therapeutics stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Choose your method of payment and add your details.
- Evaluate Orchard Therapeutics stock: The Orchard Therapeutics ticker symbol is ORTX. Is Orchard Therapeutics stock a good investment? Should you buy shares of ORTX? How do ORTX's underlying business fundamentals look? Do top analysts think Orchard Therapeutics is a good buy? Why has ORTX's stock price moved recently? (Hint: Our stock market research website can help you decide if ORTX is a good stock to buy).
- Execute your ORTX buy order: Decide if you will purchase ORTX shares at the current market price or use a limit order to buy ORTX shares at a particular price.
- Monitor your ORTX investment: Create a watchlist to keep tabs on your new investment in Orchard Therapeutics stock.
Step 1: Figure out where to buy Orchard Therapeutics stock
You will need an online brokerage account in order to access the NASDAQ market and buy ORTX stock.
Our favorite brokerage: eToro
We believe that eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global markets: From Technology to Energy, New York to London — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by opening an account with eToro today.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen the best brokerage, it's time to fill out some personal details so you are able to invest in ORTX stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.
- Input your personal info to create your new brokerage account.
- Submit your application by hitting the "Create Account" button.
Step 3: Put funds into your investment account
Now that you have opened your account on the best stock trading app for beginners, you need to deposit funds:
Watch this video walkthrough if you need help depositing money into your investment account.
Step 4: Evaluate Orchard Therapeutics stock
Once you have identified the best place to buy Orchard Therapeutics stock, it's critical to analyze their stock before you invest, so you truly understand the risk as well as the opportunity.
Orchard Therapeutics stock quick numbers
Fundamentals of ORTX
WallStreetZen was built to help average investors perform better fundamental analysis in less time.
You can view all of the due diligence checks on ORTX's stock page.
What is the fair value of ORTX stock?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge ORTX's intrinsic value.
Using relative valuations ratios:
- ORTX could be undervalued based on its P/B ratio of 1.3x, relative to Biotechnology industry P/B ratio of 5.18x
You can access additional valuation analysis on ORTX's stock here.
A quick look at ORTX Financials
Positive Financial Indicators:
- ORTX has $146.32M in cash and short term investments. This is enough to cover its annual cash burn of $84.56M.
- ORTX has cash burn of 84560000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the ORTX balance sheet.
- There are more short-term assets than long-term liabilities on the ORTX balance sheet.
Negative Financial Indicators:
- ORTX has a relatively high debt to equity ratio of 1.14.
- ORTX profit margin has gone up by 14.61 percentage points in the past year, but the company is still unprofitable.
Do Wall Street analysts think it's a good time to buy Orchard Therapeutics stock
Out of 1 sell side analysts who research ORTX, the consensus analyst rating on ORTX is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Most Recent ORTX Analyst Ratings
Pete Stavropoulos, a bottom 13% analyst from Cantor Fitzgerald maintains ORTX with a strong buy rating and raises their ORTX price target from $3.00 to $15.00, on Mar 28, 2023.
You can dig deeper into what analysts are saying on the Orchard Therapeutics stock forecast page.
Metrics for Advanced ORTX Traders
How are ORTX Revenues/Earnings doing?
Last year, ORTX revenue was $18.37M. In the past three year, ORTX's revenue has gone up by 184.78% per year. This was faster than the Biotechnology industry average of 89.01%.
Find out more about ORTX's earnings and revenue performance here.
What are ORTX insiders up to?
In the last 12 months, insiders at ORTX have bought more shares than they have sold.
Frank E. Thomas, Title President Chief Operating Officer of ORTX, was the latest ORTX insider to buy. They bought $9,180.00 worth of ORTX stock on Mar 10, 2023.
Get more info about who owns ORTX stock here.
Can I get consistent income from ORTX stock?
No, Orchard Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about ORTX?
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your ORTX buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually sufficient. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at an exact price, place a limit order.
Click the Open Trade button and eToro will execute the order.
If you need additional assistance investing in stocks on eToro, watch the how to video below:
Step 6: Monitor your ORTX investment
Now that you own some ORTX shares, you'll want to keep up with your company.
Start a watchlist to track the latest developments regarding your ORTX stock.
ORTX Feed
How to Buy Stock in Orchard Therapeutics
To reiterate, here are the 6 steps you need to take to buy Orchard Therapeutics stock right now:
- Figure out where to buy Orchard Therapeutics stock
- Create a brokerage account
- Put funds into your investment account
- Evaluate Orchard Therapeutics stock
- Execute your ORTX buy order
- Monitor your ORTX investment
If you are looking for a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you want to monitor your new investment in Orchard Therapeutics, create a watchlist on WallStreetZen today.
Trending Stock Buying Guides
FAQ
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.